

**REPORT TO THE TWENTY-THIRD HAWAII STATE  
LEGISLATURE, 2005**

**IN ACCORDANCE WITH ACT 200, PART III, SECTION 36,  
SLH 2003, ON PRESCRIPTION DRUGS FOR FEE-FOR-  
SERVICE CLIENTS INCLUDING MENTAL HEALTH  
TREATMENT**

**Department of Human Services  
Med-QUEST Division  
November 2004**

**REPORT ON PRESCRIPTION DRUGS FOR FEE-FOR-SERVICE CLIENTS  
INCLUDING MENTAL HEALTH TREATMENT FOR FY 2004, PURSUANT TO ACT  
200, PART III, SECTION 36, SLH 2003**

Act 200, Part III, Section 36, SLH 2003 appropriated funds to the Department for prescription drugs for fee-for-service clients. Section 36 requires the Department to submit a report that includes but not limited to, all expenditures made listed by prescription drugs, the number of recipients by type of drug prescribed, and possible cost containment measures for FY 2004.

**1) Expenditures Listed by Prescription Drug**

Attachment A shows a listing of the Top 100 Drugs by Amount Paid for FY 2004 in descending order. The expenditure total for the Top 100 drugs was \$75,728,702.33. Expenditures for generic drugs and other drugs not as widely prescribed was \$36,847,291.49. The total expenditures for **all** prescription drugs was \$112,575,993.82 (see Attachment D.)

**2) Number of Recipients by Type of Drug**

Attachment B shows a listing of the Top 100 Drugs by Prescription Count for FY 2004 in descending order.

Attachment C shows a Summary Listing of Unique Recipients by Therapeutic Drug Class for FY 2004. This listing provides a count of unique recipients by Drug Class (only counts each recipient once if they received multiple drugs within the same drug class).

**3) Additional Reports on Expenditures, Recipient Counts, and Prescriptions**

Attachment D shows the number of recipients by type of fee-for-service plan, the total number of prescriptions by plan, and the total amounts paid by plan for the prescriptions.

Total expenditures for all prescription drugs: \$112,575,993.82  
Total number of claims paid: 1,748,937  
Average prescription cost: \$64.37 (\$112,575,994/1,748,937)  
Total number of recipients unduplicated: 43,189

Attachment E shows the average number of recipients per month and the average number of prescriptions per recipient.

Monthly average of utilizing recipients: 27,518  
Average number of prescriptions per month: 5.2

**4) Drugs Granted Prior Authorization**

Attachment F shows a listing of the top drugs on the PDL that were granted prior authorization.

Attachment G shows a listing of the top 25 other drugs that are not on the PDL but are granted prior authorization by the Medicaid program.

## 5) Cost Containment Measures for Fiscal Year 2004

The Department implemented these cost containment measures:

- a) Mandatory generic prescriptions savings

Summary of Mandatory Generic Drug Prescriptions for FY 2004

Rx Count	Total Max Amt Billed	Amount Allowed	Difference=Amount Saved
59,518	\$4,491,741.61	\$2,558,545.16	<b>\$1,933,196.45</b>

- b) Imposed quantity limits for certain medications that are over-utilized, requiring a prior authorization to justify that large quantities are medically necessary and appropriate.
- c) Imposed quantity limits to reduce overpayments to providers who bill for overstated quantities, which leads to disputes with drug manufacturers on drug rebate amounts.
- d) The pharmacy audit contractor audited the pharmacy fiscal agent and more pharmacies. The audit reports have shown problem areas that needed to be addressed such as incorrect provider billings, “lost” prescriptions, “lost” drug purchase invoices, etc. Also, the fiscal agent audit covering August 1, 2001 through December 31, 2002 showed deficiencies for which ACS and MQD are finalizing resolution in the clinical services area. ACS prepared a gap analysis to identify deficiencies and remedies and submitted outstanding deliverables on 11/12/04. A letter was submitted by ACS to MQD on 11/15/04 detailing additional services to be provided by Heritage (wholly owned subsidiary of ACS) and ACS will be holding telephone conferences with MQD to explain and validate outstanding clinical services being met. The goal is to have final resolution before November 30, 2004.
- e) Additional prior authorizations for highly utilized medications or new very expensive drugs were implemented to reduce inappropriate usage.
- f) Certain outlier prescribers were targeted to receive “report cards” comparing their prescribing practices to their peers. As a result, the utilization patterns for a number of the outliers changed after these report cards were issued. This was a small scale project that involved only prescribers of high dose Zyprexa.
- g) A preferred drug list (PDL) was initially started in the fall of 2003 through a short-term contract amendment with the current Pharmacy Fiscal Agent, Affiliated Computer Services (ACS). In 2004, a new contractor, First Health Services Corporation, was competitively awarded a 15 month contract with a one year extension provision for the PDL program. Attachment H shows savings of \$261,652.47 for the Phase I PDL therapeutic class implementation and the therapeutic classes impacted. The Federal rebates for this period are still being collected. The State supplemental rebate contracts

are being finalized and the cost of implementing and maintaining the program was not included in this report.

#### **6) Cost Containment Measures Proposed for Fiscal Year 2005**

The MQD plans to implement or continue with the following:

- a) Expand the preferred drug list with supplemental rebates.
- b) Conduct audits of pharmacies and the pharmacy fiscal agent.
- c) Prior authorize high cost, highly utilized medications when appropriate.
- d) Place limits on various medications to encourage appropriate utilization.
- e) Consider revising the state maximum allowable cost program to increase savings on generic drugs.
- f) Increase prescriber profiling to show more outliers how much they differ from their peers.

Attachments

## ATTACHMENT A

**Top 100 Drugs by Amount Paid for FY 2004 (7/01/2003 - 6/30/2004)**

Drug	Amount Paid
ZYPREXA	\$6,181,443.69
LIPITOR	\$3,427,941.99
SEROQUEL	\$2,896,942.17
RISPERDAL	\$2,748,524.24
NEURONTIN	\$2,180,504.48
PLAVIX	\$2,025,110.24
MORPHINE	\$1,650,379.67
DEPAKOTE	\$1,617,904.08
PRAVACHOL	\$1,593,718.75
OXYCONTIN	\$1,485,730.17
ACTOS	\$1,467,446.74
ABILIFY	\$1,466,368.77
FOSAMAX	\$1,427,075.88
CELEBREX	\$1,407,816.56
ADVAIR	\$1,386,582.74
DURAGESIC	\$1,330,238.13
ZOLOFT	\$1,244,225.51
HEMOFIL-M	\$1,112,383.46
ZOCOR	\$1,092,732.27
AVANDIA	\$1,068,929.33
GEODON	\$1,055,915.13
CLOZAPINE	\$1,024,027.38
METFORMIN	\$992,167.66
COZAAR	\$979,575.45
VIOXX	\$976,587.25
ACTIQ	\$933,481.38
LISINAPRIL	\$920,037.28
ARICEPT	\$878,972.19
MARINOL	\$868,392.09
SINGULAIR	\$836,201.36
PLENDIL	\$794,027.81
RENAGEL	\$770,735.98
ACTONEL	\$763,328.07
AMBIEN	\$713,736.92
TOPAMAX	\$697,376.76
PROCRIT	\$618,030.65
EFFEXOR	\$617,038.74
WELLBUTRIN	\$605,402.30
PREVACID	\$601,151.82
HYDROCODONE/APAP	\$543,524.94
EVISTA	\$529,207.39
RECOMBINATE	\$514,596.22

NIFEDIPINE	\$512,782.11
TOPROL	\$496,998.85
LOVASTATIN	\$486,213.83
CELEXA	\$473,543.54
MEGESTROL	\$444,261.93
ALBUTEROL	\$440,703.07
LAMICTAL	\$417,372.82
PROTONIX	\$417,103.59
CIPROFLOXACIN	\$406,668.50
EXELON	\$406,605.48
NOVOLIN	\$399,789.22
PAROXETINE	\$398,146.07
COREG	\$396,009.64
FLOMAX	\$388,849.38
PAXIL	\$384,693.27
KALETRA	\$382,620.06
SEROSTIM	\$382,354.30
VIREAD	\$381,239.46
COMBIVENT	\$380,573.95
COMBIVIR	\$373,989.15
HELIXATE	\$366,401.37
DILTIAZEM	\$365,538.36
RANITIDINE	\$351,598.21
MIACALCIN	\$349,771.06
ATACAND	\$346,973.25
TEGRETOL	\$333,051.63
GLEEVEC	\$331,787.05
EPIVIR	\$330,910.46
DIOVAN	\$328,480.05
MIRTAZAPINE	\$325,485.86
LAMISIL	\$322,860.16
DETROL	\$320,428.29
LEXAPRO	\$313,956.76
BENICAR	\$313,326.41
KEPPRA	\$307,810.44
HUMALOG	\$305,418.89
GLYBURIDE	\$304,072.91
HUMATE-P	\$303,645.80
TRILEPTAL	\$302,636.98
HYZAAR	\$302,558.28
LEVAQUIN	\$299,963.47
FORTEO	\$297,502.67
FLOVENT	\$294,296.84
VIRACEPT	\$290,036.30
DILANTIN	\$284,477.43
ENBREL	\$280,887.49
SYNAGIS	\$268,863.77
NEXIUM	\$259,375.45

LANTUS	\$259,050.79
PEGASYS	\$256,311.23
SUSTIVA	\$255,760.41
CIPRO	\$253,076.34
WARFARIN	\$251,850.27
ISOSORBIDE	\$251,801.39
DIFLUCAN	\$251,176.04
FLUOXETINE	\$249,934.15
NEUPOGEN	\$244,911.98
CARBIDOPA/LEVO	\$236,682.23
Total Amount Paid for FY 2004	\$75,728,702.33

ATTACHMENT B

<b>Top 100 Drugs by Rx Count for FY 2004 (7/01/2003 - 6/30/2004)</b>	
Drug	Rx Count
LIPITOR	41,511
ASPIRIN	34,193
LISINAPRIL	33,474
HYDROCODONE/APAP	33,119
FUROSEMIDE	26,215
ALBUTEROL	21,619
DOCUSATE	21,142
METFORMIN	19,459
FOSAMAX	18,268
RANITIDINE	16,562
ZYPREXA	16,524
PLAVIX	16,464
NEURONTIN	16,177
COZAAR	15,496
CIMETIDINE	15,197
ATENOLOL	15,037
TOPROL	14,653
CALCIUM	13,853
PLENDIL	13,799
DEPAKOTE	13,734
PRAVACHOL	13,529
ACETAMINOPHEN	13,383
DIGITEK	13,330
ZOLOFT	13,294
SEROQUEL	13,292
CELEBREX	13,122
IBUPROFEN	12,873
DIAZEPAM	11,959
SYNTHROID	11,810
ACETAMINOPHEN/COD	11,674
RISPERDAL	11,474
GLYBURIDE	10,770
PREDNISONE	10,748
VIOXX	10,526
ACTONEL	10,517
CEPHALEXIN	10,269
WARFARIN	10,241
ACTOS	9,877
TRAZODONE	9,777
ADVAIR	9,668
ALPRAZOLAM	9,615
HYDROCHLOROTHIAZIDE	9,285



AMBIEN	9,281
ISOSORBIDE	9,272
SINGULAIR	9,234
CLONAZEPAM	9,206
POTASSIUM	9,102
ALLOPURINOL	9,084
AVANDIA	8,907
FERROUS	8,666
DILANTIN	8,627
NIFEDIPINE	8,587
ZOCOR	8,441
LOVASTATIN	8,339
GLIPIZIDE	8,291
PROMETHAZINE	8,113
PROMETHAZINE/CODEINE	7,913
DILTIAZEM	7,739
FOLIC	7,709
BENZTROPINE	7,643
LEVOTHROID	7,591
AMOXICILLIN	7,550
NOVOLIN	7,520
LORAZEPAM	7,470
CLOZAPINE	7,349
METOPROLOL	7,277
DIPHENHYDRAMINE	7,276
TRIAMCINOLONE	7,232
CARISOPRODOL	7,186
HYDROXYZINE	7,117
MORPHINE	7,077
ARICEPT	6,514
BENICAR	6,509
OYST-CAL-500	6,481
FLUOXETINE	6,350
EVISTA	6,344
NAPROXEN	6,216
SODIUM	6,056
MECLIZINE	5,928
ATACAND	5,915
WELLBUTRIN	5,804
FLOMAX	5,683
COMBIVENT	5,582
DIOVAN	5,453
OXYCODONE	5,423
CELEXA	5,277
KLOR-CON	5,244
EFFEXOR	5,167
TEGRETOL	5,161
TRIAMTERENE/HCTZ	5,035

COLCHICINE	5,027
SENNA-GEN	4,983
OYSTER	4,949
OXYCONTIN	4,889
HYZAAR	4,874
ANTACID	4,827
SULFAMETHOXAZOLE/TMP	4,803
PAROXETINE	4,737
PREMARIN	4,541
ENDOCET	4,539
Total Rx Count	1,060,639

ATTACHMENT C

**Summary of Unique Recipients by Therapeutic Drug Class (7/01/03 through 6/30/04)**

Specific Thera Class Code	Spec Thera Class Description	Count Unique Utilizers
A1A	DIGITALIS GLYCOSIDES	2200
A1B	XANTHINES	694
A1C	INOTROPIC DRUGS	26
A1D	GENERAL BRONCHODILATOR AGENTS	991
A2A	ANTIARRHYTHMICS	425
A4A	HYPOTENSIVES,VASODILATORS	402
A4B	HYPOTENSIVES,SYMPATHOLYTIC	886
A4C	HYPOTENSIVES,GANGLIONIC BLOCKERS	1
A4D	HYPOTENSIVES, ACE INHIBITORS	8212
A4F	HYPOTENSIVES,ANGIOTENSIN RECEPTOR ANTAGONIST	6596
A4K	ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATION	723
A4Y	HYPOTENSIVES,MISCELLANEOUS	132
A7B	VASODILATORS,CORONARY	2805
A7C	VASODILATORS,PERIPHERAL	11
A9A	CALCIUM CHANNEL BLOCKING AGENTS	6749
B0A	GENERAL INHALATION AGENTS	54
B1B	PULMONARY ANTI-HTN, ENDOTHELIN RECEPTOR ANTAGONIST	4
B3A	MUCOLYTICS	48
B3J	EXPECTORANTS	7883
B3K	COUGH AND/OR COLD PREPARATIONS	7726
B3K	SYMPATHOMIMETIC AGENTS	2
B3T	NON-NARCOTIC ANTITUSSIVE AND EXPECTORANT COMB.	1
C0B	WATER	184
C0D	ANTI-ALCOHOLIC PREPARATIONS	24
C0K	BICARBONATE PRODUCING/CONTAINING AGENTS	31
C1A	ELECTROLYTE DEPLETERS	996
C1B	SODIUM/SALINE PREPARATIONS	826
C1D	POTASSIUM REPLACEMENT	3046
C1F	CALCIUM REPLACEMENT	4683
C1H	MAGNESIUM SALTS REPLACEMENT	395
C1P	PHOSPHATE REPLACEMENT	78
C1W	ELECTROLYTE MAINTENANCE	168
C3B	IRON REPLACEMENT	2534
C3C	ZINC REPLACEMENT	142
C3H	IODINE CONTAINING AGENTS	42
C3M	MINERAL REPLACEMENT,MISCELLANEOUS	7
C4G	INSULINS	2415
C4K	HYPOGLYCEMICS, INSULIN-RELEASE STIMULANT TYPE	4662
C4L	HYPOGLYCEMICS, BIGUANIDE TYPE (NON-SULFONYLUREAS)	3092
C4M	HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIB TYPE (N-S)	136
C4N	HYPOGLYCEMICS, INSULIN-RESPONSE ENHANCER (N-S)	2829

C5B	PROTEIN REPLACEMENT	1
C5F	DIETARY SUPPLEMENT, MISCELLANEOUS	1
C5G	FOOD OILS	1
C5J	IV SOLUTIONS: DEXTROSE-WATER	236
C5K	IV SOLUTIONS: DEXTROSE-SALINE	154
C5M	IV SOLUTIONS: DEXTROSE AND LACTATED RINGERS	2
C6A	VITAMIN A PREPARATIONS	1
C6B	VITAMIN B PREPARATIONS	111
C6C	VITAMIN C PREPARATIONS	172
C6D	VITAMIN D PREPARATIONS	391
C6E	VITAMIN E PREPARATIONS	13
C6F	PRENATAL VITAMIN PREPARATIONS	179
C6G	GERIATRIC VITAMIN PREPARATIONS	16
C6H	PEDIATRIC VITAMIN PREPARATIONS	971
C6K	VITAMIN K PREPARATIONS	99
C6L	VITAMIN B12 PREPARATIONS	225
C6L	VITAMIN B PREPARATIONS	16
C6M	FOLIC ACID PREPARATIONS	1269
C6N	NIACIN PREPARATIONS	134
C6Q	VITAMIN B6 PREPARATIONS	9
C6T	VITAMIN B1 PREPARATIONS	10
C6Z	MULTIVITAMIN PREPARATIONS	1561
C6Z	VITAMIN B PREPARATIONS	51
C7A	HYPERURICEMIA TX - PURINE INHIBITORS	1557
C7B	DECARBOXYLASE INHIBITORS	4
C7D	METABOLIC DEFICIENCY AGENTS	53
C8A	METALLIC POISON,AGENTS TO TREAT	12
C8B	ACID AND ALKALI POISON ANTIDOTES	2
D1A	PERIODONTAL COLLAGENASE INHIBITORS	6
D1D	DENTAL AIDS AND PREPARATIONS	1223
D2A	FLUORIDE PREPARATIONS	890
D4B	ANTACIDS	3002
D4B	CALCIUM REPLACEMENT	2
D4D	ANTIDIARRHEAL MICROORGANISMS AGENTS	1
D4E	ANTI-ULCER PREPARATIONS	366
D4F	ANTI-ULCER-H.PYLORI AGENTS	222
D4H	ORAL MUCOSITIS/STOMATITIS AGENTS	3
D4I	ORAL MUCOSITIS/STOMATITIS ANTI-INFLAMMATORY AGENT	11
D4K	GASTRIC ACID SECRETION REDUCERS	9148
D4N	ANTIFLATULENTS	44
D5A	FAT ABSORPTION DECREASING AGENTS	31
D5P	INTESTINAL ADSORBENTS AND PROTECTIVES	5
D6A	DRUGS TO TX CHRONIC INFLAMM. DISEASE OF COLON	9
D6C	IRRITABLE BOWEL SYND. AGENT,5HT-3 ANTAGONIST-TYPE	1
D6D	ANTIDIARRHEALS	2273
D6E	IRRITABLE BOWEL SYND. AGENT,5HT-4 PARTIAL AGONIST	47
D6F	DRUG TX-CHRONIC INFLAM. COLON DX,5-AMINOSALICYLAT	55
D6S	AMMONIA INHIBITORS	2
D6S	LAXATIVES AND CATHARTICS	9336
D7A	BILE SALTS	114

D7L	BILE SALT SEQUESTRANTS	329
D8A	PANCREATIC ENZYMES	295
D9A	AMMONIA INHIBITORS	950
F1A	ANDROGENIC AGENTS	170
G1A	ESTROGENIC AGENTS	1342
G1B	ESTROGEN/ANDROGEN COMBINATIONS	23
G2A	PROGESTATIONAL AGENTS	504
G3A	OXYTOCICS	10
G8A	CONTRACEPTIVES,ORAL	387
G8C	CONTRACEPTIVES,INJECTABLE	205
G8F	CONTRACEPTIVES,TRANSDERMAL	54
G9B	CONTRACEPTIVES, INTRAVAGINAL, SYSTEMIC	6
H0A	LOCAL ANESTHETICS	833
H0E	AGENTS TO TREAT MULTIPLE SCLEROSIS	39
H1A	ALZHEIMER'S THERAPY, NMDA RECEPTOR ANTAGONISTS	247
H2A	CENTRAL NERVOUS SYSTEM STIMULANTS	11
H2B	GENERAL ANESTHETICS,INHALANT	1
H2C	GENERAL ANESTHETICS,INJECTABLE	478
H2D	BARBITURATES	453
H2E	SEDATIVE-HYPNOTICS,NON-BARBITURATE	4124
H2F	ANTI-ANXIETY DRUGS	5561
H2G	ANTI-PSYCHOTICS,PHENOTHIAZINES	610
H2J	ANTIDEPRESSANTS O.U.	1
H2M	ANTI-MANIA DRUGS	417
H2S	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	5901
H2T	ALCOHOL,SYSTEMIC USE	1
H2U	TRICYCLIC ANTIDEPRESSANTS & REL. NON-SEL. RU-INHIB	1679
H2V	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	282
H2W	TRICYCLIC ANTIDEPRESSANT/PHENOTHIAZINE COMBINATNS	22
H2X	TRICYCLIC ANTIDEPRESSANT/BENZODIAZEPINE COMBINATNS	6
H2Z	BENZODIAZEPINE ANTAGONISTS	4
H3A	ANALGESICS,NARCOTICS	16521
H3D	ANALGESIC/ANTIPYRETICS, SALICYLATES	7189
H3E	ANALGESIC/ANTIPYRETICS,NON-SALICYLATE	9285
H3F	ANTIMIGRAINE PREPARATIONS	421
H3H	ANALGESICS NARCOTIC, ANESTHETIC ADJUNCT AGENTS	386
H3T	NARCOTIC ANTAGONISTS	42
H4B	ANTICONVULSANTS	7083
H6A	ANTIPARKINSONISM DRUGS,OTHER	752
H6B	ANTIPARKINSONISM DRUGS,ANTICHOLINERGIC	1153
H6C	ANTITUSSIVES,NON-NARCOTIC	883
H6E	EMETICS	1
H6H	SKELETAL MUSCLE RELAXANTS	3204
H6I	AMYOTROPHIC LATERAL SCLEROSIS AGENTS	8
H6J	ANTIEMETIC/ANTIVERTIGO AGENTS	3762
H7B	ALPHA-2 RECEPTOR ANTAGONIST ANTIDEPRESSANTS	1014
H7C	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	811
H7D	NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIB (NDRIS)	1317
H7E	SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (SARIS)	1968
H7J	MAOIS - NON-SELECTIVE & IRREVERSIBLE	3

H7N	SMOKING DETERRENTS, OTHER	61
H7O	ANTIPSYCHOTICS,DOPAMINE ANTAGONISTS,BUTYROPHENONES	727
H7P	ANTIPSYCHOTICS,DOPAMINE ANTAGONISTS, THIOXANTHENES	72
H7R	ANTIPSYCH,DOPAMINE ANTAG.,DIPHENYLBUTYLPIPERIDINES	6
H7S	ANTIPSYCHOTICS,DOPAMINE ANTAGONST,DIHYDROINDOLONES	6
H7T	ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,& SEROTONIN ANTAG	4877
H7U	ANTIPSYCHOTICS, DOPAMINE & SEROTONIN ANTAGONISTS	4
H7X	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	690
H7Y	TX FOR ATTENTION DEFICIT-HYPERACT.(ADHD), NRI-TYPE	81
H7Z	SSRI &ANTIPSYCH,ATYP,DOPAMINE&SEROTONIN ANTAG COMB	13
J1A	PARASYMPATHETIC AGENTS	118
J1B	CHOLINESTERASE INHIBITORS	1575
J2A	BELLADONNA ALKALOIDS	140
J2B	ANTICHOLINERGICS,QUATERNARY AMMONIUM	109
J2D	ANTICHOLINERGICS/ANTISPASMODICS	771
J3A	SMOKING DETERRENT AGENTS (GANGLIONIC STIM,OTHERS)	1
J5A	ADRENERGIC AGENTS,CATECHOLAMINES	37
J5B	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	130
J5D	BETA-ADRENERGIC AGENTS	7462
J5E	SYMPATHOMIMETIC AGENTS	1635
J5F	ANAPHYLAXIS THERAPY AGENTS	126
J5G	BETA-ADRENERGICS AND GLUCOCORTICOIDS COMBINATION	2511
J5H	ADRENERGIC VASOPRESSOR AGENTS	29
J7A	ALPHA/BETA-ADRENERGIC BLOCKING AGENTS	959
J7B	ALPHA-ADRENERGIC BLOCKING AGENTS	846
J7C	BETA-ADRENERGIC BLOCKING AGENTS	6306
J8A	ANOREXIC AGENTS	15
J9A	INTESTINAL MOTILITY STIMULANTS	963
J9B	ANTISPASMODIC AGENTS	5
L0B	TOPICAL/MUCOUS MEMBR./SUBCUT. ENZYMES	193
L0C	DIABETIC ULCER PREPARATIONS, TOPICAL	22
L1A	ANTIPSORIATIC AGENTS,SYSTEMIC	24
L1B	ACNE AGENTS,SYSTEMIC	13
L2A	EMOLLIENTS	150
L3A	PROTECTIVES	7
L3P	ANTIPRURITICS, TOPICAL	40
L4A	ASTRINGENTS	16
L5A	KERATOLYTICS	310
L5B	SUNSCREENS	1
L5E	ANTISEBORRHEIC AGENTS	479
L5F	ANTIPSORIATICS AGENTS	125
L5G	ROSACEA AGENTS, TOPICAL	86
L5H	ACNE AGENTS, TOPICAL	40
L6A	IRRITANTS/COUNTER-IRRITANTS	33
L7A	SHAMPOOS/LOTION	7
L8B	ANTIPERSPIRANTS	11
L9A	TOPICAL AGENTS,MISCELLANEOUS	77
L9B	VITAMIN A DERIVATIVES	222
L9D	TOPICAL HYPERPIGMENTATION AGENTS	1
M0B	PLASMA PROTEINS	11

M0E	ANTIHEMOPHILIC FACTORS	13
M0F	FACTOR IX PREPARATIONS	3
M4B	IV FAT EMULSIONS	15
M4E	LIPOTROPICS	11827
M4G	HYPERGLYCEMICS	98
M4I	ANTIHYPERTENSIVE(HMGCOA) & CALCIUM CHANNEL BLOCKER CMB	7
M9A	TOPICAL HEMOSTATICS	29
M9D	ANTIFIBRINOLYTIC AGENTS	6
M9F	THROMBOLYTIC ENZYMES	40
M9K	HEPARIN AND RELATED PREPARATIONS	490
M9L	ORAL ANTICOAGULANTS,COUMARIN TYPE	1434
M9P	PLATELET AGGREGATION INHIBITORS	2792
M9R	COAGULANTS	11
M9S	HEMORRHOLOGIC AGENTS	110
N1B	HEMATINICS,OTHER	271
N1C	LEUKOCYTE (WBC) STIMULANTS	80
N1D	PLATELET REDUCING AGENTS	7
N1E	PLATELET PROLIFERATION STIMULANTS	3
P1A	GROWTH HORMONES	26
P1B	SOMATOSTATIC AGENTS	5
P1E	ADRENOCORTICOTROPIC HORMONES	9
P1F	PITUITARY SUPPRESSIVE AGENTS	38
P1M	LHRH(GNRH) AGONIST ANALOG PITUITARY SUPPRESSANTS	1
P1P	LHRH(GNRH)AGNST PIT.SUP-CENTRAL PRECOCIOUS PUBERTY	4
P2B	ANTIDIURETIC AND VASOPRESSOR HORMONES	72
P3A	THYROID HORMONES	3148
P3L	ANTITHYROID PREPARATIONS	88
P4B	BONE FORMATION STIM. AGENTS - PARATHYROID HORMONE	115
P4L	BONE RESORPTION INHIBITORS	5857
P4M	CALCIMIMETIC,PARATHYROID CALCIUM ENHANCER	30
P5A	GLUCOCORTICIDS	5856
P5S	MINERALOCORTICIDS	104
Q2A	OCULAR PHOTOACTIVATED VESSEL-OCCLUDING AGENTS	5
Q2C	OPHTHALMIC ANTI-INFLAMMATORY IMMUNOMODULATOR-TYPE	104
Q3A	RECTAL PREPARATIONS	613
Q3B	RECTAL/LOWER BOWEL PREP.,GLUCOCORT. (NON-HEMORR)	4
Q3D	HEMORRHOIDAL PREPARATIONS	85
Q3E	CHRONIC INFLAM. COLON DX, 5-A-SALICYLAT,RECTAL TX	15
Q3H	HEMORRHOIDALS, LOCAL RECTAL ANESTHETICS	4
Q3S	LAXATIVES, LOCAL/RECTAL	2776
Q4B	VAGINAL ANTISEPTICS	1
Q4F	VAGINAL ANTIFUNGALS	521
Q4K	VAGINAL ESTROGEN PREPARATIONS	286
Q4W	VAGINAL ANTIBIOTICS	174
Q5B	TOPICAL PREPARATIONS,ANTIBACTERIALS	265
Q5C	TOPICALS, HYPERTRICHOTIC AGENTS	1
Q5F	TOPICAL ANTIFUNGALS	5991
Q5H	TOPICAL LOCAL ANESTHETICS	327
Q5K	TOPICAL IMMUNOSUPPRESSIVE AGENTS	382
Q5N	TOPICAL ANTINEOPLASTIC & PREMALIGNANT LESION AGENTS	61

Q5P	TOPICAL ANTI-INFLAMMATORY STEROIDAL	7988
Q5R	TOPICAL ANTIPARASITICS	998
Q5S	TOPICAL SULFONAMIDES	737
Q5V	TOPICAL ANTIVIRALS	323
Q5W	TOPICAL ANTIBIOTICS	4299
Q5X	TOPICAL ANTIBIOTICS/ANTIINFLAMMATORY,STEROIDAL	18
Q6A	OPHTHALMIC PREPARATIONS, MISCELLANEOUS	12
Q6B	EYE ANTI-INFECTIVES (RX ONLY)	1
Q6C	EYE VASOCONSTRICTORS (RX ONLY)	565
Q6D	EYE VASOCONSTRICTORS (OTC ONLY)	1
Q6E	EYE IRRIGATIONS	4
Q6G	MIOTICS/OTHER INTRAOC. PRESSURE REDUCERS	1609
Q6H	EYE LOCAL ANESTHETICS	24
Q6I	EYE ANTIBIOTIC-CORTICOID COMBINATIONS	1574
Q6J	MYDRIATICS	158
Q6P	EYE ANTIINFLAMMATORY AGENTS	1847
Q6R	EYE ANTIHISTAMINES	802
Q6S	EYE SULFONAMIDES	761
Q6T	ARTIFICIAL TEARS	1903
Q6U	OPHTHALMIC MAST CELL STABILIZERS	117
Q6V	EYE ANTIVIRALS	24
Q6W	OPHTHALMIC ANTIBIOTICS	2173
Q6Y	EYE PREPARATIONS, MISCELLANEOUS (OTC)	172
Q7A	NOSE PREPARATIONS, MISCELLANEOUS (RX)	115
Q7D	NOSE PREPARATIONS, VASOCONSTRICTORS(OTC)	3
Q7E	NASAL ANTIHISTAMINE	166
Q7H	NASAL MAST CELL STABILIZERS AGENTS	12
Q7P	NASAL ANTI-INFLAMMATORY STEROIDS	2673
Q7W	NOSE PREPARATIONS ANTIBIOTICS	36
Q7Y	NOSE PREPARATIONS, MISCELLANEOUS (OTC)	2
Q8B	EAR PREPARATIONS, MISC. ANTI-INFECTIVES	99
Q8F	OTIC PREPARATIONS,ANTI-INFLAMMATORY-ANTIBIOTICS	103
Q8H	EAR PREPARATIONS,LOCAL ANESTHETICS	127
Q8R	EAR PREPARATIONS,EAR WAX REMOVERS	467
Q8W	EAR PREPARATIONS,ANTIBIOTICS	1403
Q9B	BENIGN PROSTATIC HYPERTROPHY/MICTURITION AGENTS	1148
R1A	URINARY TRACT ANTISPASMODIC/ANTIINCONTINENCE AGENT	1131
R1B	OSMOTIC DIURETICS	12
R1E	CARBONIC ANHYDRASE INHIBITORS	168
R1F	THIAZIDE AND RELATED DIURETICS	2939
R1H	POTASSIUM SPARING DIURETICS	791
R1L	POTASSIUM SPARING DIURETICS IN COMBINATION	1054
R1M	LOOP DIURETICS	5062
R1R	URICOSURIC AGENTS	93
R1S	URINARY PH MODIFIERS	113
R5A	URINARY TRACT ANESTHETIC/ANALGESIC AGNT (AZO-DYE)	627
R5B	URINARY TRACT ANALGESIC AGENTS	9
S2A	COLCHICINE	1330
S2B	NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE	13559
S2H	ANTI-INFLAMMATORY/ANTIARTHRITICS AGENTS, MISC.	2



S2I	ANTI-INFLAMMATORY, PYRIMIDINE SYNTHESIS INHIBITOR	22
S2J	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	44
S2M	ANTI-FLAM. INTERLEUKIN-1 RECEPTOR ANTAGONIST	1
S2N	ANTI-ARTHRITIC, FOLATE ANTAGONIST AGENTS	1
S2P	NSAID, COX INHIBITOR-TYPE & PROTON PUMP INHIB COMB	34
S7A	NEUROMUSCULAR BLOCKING AGENTS	70
U5B	HERBAL DRUGS	3
U6E	OINTMENT/CREAM BASES	1
U6H	SOLVENTS	86
U6N	VEHICLES	465
U6W	BULK CHEMICALS	6
U7A	SUSPENDING AGENTS	10
U7N	SWEETENERS	1
V1A	ALKYLATING AGENTS	102
V1B	ANTIMETABOLITES	300
V1C	VINCA ALKALOIDS	28
V1D	ANTIBIOTIC ANTINEOPLASTICS	7
V1E	STEROID ANTINEOPLASTICS	1087
V1F	ANTINEOPLASTICS,MISCELLANEOUS	164
V1I	CHEMOTHERAPY RESCUE/ANTIDOTE AGENTS	59
V1J	ANTIANDROGENIC AGENTS	93
V1K	ANTINEOPLAST EGF RECEPTOR BLOCKER RCMB MC ANTIBODY	4
V1K	ANTINEOPLASTICS ANTIBODY/ANTIBODY-DRUG COMPLEXES	4
V1N	SELECTIVE RETINOID X RECEPTOR AGONISTS (RXR)	1
V1O	ANTINEOPLASTIC LHRH(GNRH) AGONIST,PITUITARY SUPPR.	21
V1Q	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	46
V1T	SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)	163
V1W	ANTINEOPLAST EGF RECEPTOR BLOCKER RCMB MC ANTIBODY	3
V1X	ANTINEOPLAST HUM VEGF INHIBITOR RECOMB MC ANTIBODY	1
W1A	PENICILLINS	12504
W1C	TETRACYCLINES	2008
W1D	MACROLIDES	4542
W1F	AMINOGLYCOSIDES	184
W1G	ANTITUBERCULAR ANTIBIOTICS	63
W1J	VANCOMYCIN AND DERIVATIVES	139
W1K	LINCOSAMIDES	1171
W1L	ANTIBIOTICS, MISCELLANEOUS, OTHER	4
W1O	OXAZOLIDINONES	25
W1P	BETALACTAMS	6
W1Q	QUINOLONES	7489
W1S	CARBAPENEMS (THIENAMYCINS)	22
W1W	CEPHALOSPORINS - 1ST GENERATION	6709
W1X	CEPHALOSPORINS - 2ND GENERATION	1124
W1Y	CEPHALOSPORINS - 3RD GENERATION	1055
W1Z	CEPHALOSPORINS - 4TH GENERATION	62
W2A	ABSORBABLE SULFONAMIDES	3076
W2E	ANTI-MYCOBACTERIUM AGENTS	28
W2F	NITROFURAN DERIVATIVES	772
W2G	CHEMOTHERAPEUTICS, ANTIBACTERIAL, MISC.	118
W3A	ANTIFUNGAL ANTIBIOTICS	367

W3B	ANTIFUNGAL AGENTS	1855
W4A	ANTIMALARIAL DRUGS	1260
W4C	AMEBACIDES	1
W4E	ANAEROBIC ANTIPROTOZOAL-ANTIBACTERIAL AGENTS	604
W4K	ANTIPROTOZOAL DRUGS,MISCELLANEOUS	3
W4L	ANTHELMINTICS	218
W4M	ANTIPARASITICS	3
W4P	ANTILEPROTICS	46
W5A	ANTIVIRALS, GENERAL	1439
W5C	ANTIVIRALS, HIV-SPECIFIC, PROTEASE INHIBITORS	152
W5D	ANTIVIRAL MONOCLONAL ANTIBODIES	52
W5F	HEPATITIS B TREATMENT AGENTS	30
W5G	HEPATITIS C TREATMENT AGENTS	65
W5I	ANTIVIRALS, HIV-SPECIFIC, NUCLEOTIDE ANALOG, RTI	133
W5J	ANTIVIRALS, HIV-SPECIFIC, NUCLEOSIDE ANALOG, RTI	225
W5K	ANTIVIRALS, HIV-SPECIFIC, NON-NUCLEOSIDE, RTI	135
W5L	ANTIVIRALS, HIV-SPEC., NUCLEOSIDE ANALOG, RTI COMB	116
W5M	ANTIVIRALS, HIV-SPECIFIC, PROTEASE INHIBITOR COMB	80
W5N	ANTIVIRALS, HIV-SPECIFIC, FUSION INHIBITORS	7
W7B	VIRAL/TUMORIGENIC VACCINES	85
W7C	INFLUENZA VIRUS VACCINES	834
W7H	ENTERIC VIRUS VACCINES	5
W7K	ANTISERA	23
W7L	GRAM POSITIVE COCCI VACCINES	149
W7N	TOXIN-PRODUCING BACILLI VACCINES/TOXOIDS	4
W7Q	GRAM NEGATIVE COCCI VACCINES	1
W7Z	VACCINE/TOXOID PREPARATIONS,COMBINATIONS	89
W8F	IRRIGANTS	414
Z1E	ANTIOXIDANT AGENTS	1
Z2A	ANTIHISTAMINES	7299
Z2E	IMMUNOSUPPRESSIVES	186
Z2F	MAST CELL STABILIZERS	48
Z2G	IMMUNOMODULATORS	50
Z2L	MONOCLONAL ANTIBODIES TO IMMUNOGLOBULIN E(IGE)	10
Z4B	LEUKOTRIENE RECEPTOR ANTAGONISTS	1697

ATTACHMENT D

**Hawaii Report Of Unique Utilizers In FY 2004 By Plan**

Group Number/Name	Plan ID	Count Unique Utilizers	Rx Count	Total Amount Paid
HAWAII MEDICAID FEE-FOR-SERVICE PROGRAM	100	40,907	1,507,548	\$102,542,033.87
LONG TERM CARE	200	4,203	224,714	\$9,160,151.24
COMMUNITY CARE SERVICES	300	573	15,173	\$756,035.07
LONG TERM CARE MINUS BEHAVIORIAL HEALTH	310	3	54	\$9,899.32
HOSPICE	500	29	264	\$18,632.39
SHOTT	600	41	1,184	\$89,241.93
HAWAII MEDICAID FEE-FOR-SERVICE PROGRAM	Sum:	45,756	1,748,937	\$112,575,993.82

Total <b>Unique</b> Utilizers and Rx Counts for FY 2003	All Plans	43,189*	1,748,937	\$112,575,993.82
---	-----------	---------	-----------	------------------

\* Unduplicated count

ATTACHMENT E

**Average Rxs Per Recipient Per Month For FY 2004**

Plans 100, 200, 300, 310, 500, & 600

Service Month Ending	Count Unique Utilizing Recipients	Rx Count	Average Number of Rxs Per Recipient
7/31/2003	27,377	144,505	5.28
8/31/2003	27,192	139,481	5.13
9/30/2003	27,185	142,749	5.25
10/31/2003	27,687	148,714	5.37
11/30/2003	26,901	134,461	5.00
12/31/2003	27,762	153,462	5.53
1/31/2004	27,841	149,954	5.39
2/29/2004	27,188	137,352	5.05
3/31/2004	28,211	157,295	5.58
4/30/2004	27,745	148,730	5.36
5/31/2004	27,480	142,662	5.19
6/30/2004	27,641	149,579	5.41
<b>Average:</b>	<b>27,518</b>	<b>145,745</b>	<b>5.29</b>

ATTACHMENT F

**Top "PDL" Drugs Granted Prior Authorization**

Rank	Drug Name	Amount Paid	Rx Count
1	PREVACID 30MG CAPSULE DR	\$10,535.71	63
2	BEXTRA 20MG TABLET	\$1,571.05	15
3	BEXTRA 10MG TABLET	\$1,329.83	10
4	OMEPRAZOLE 20MG CAPSULE DR	\$883.06	2
5	PRILOSEC 40MG CAPSULE DR	\$364.92	2
6	CELEBREX 200MG CAPSULE PREVACID 15MG SUSPENSION	\$332.48	4
7	DR	\$260.58	2
8	DIOVAN 160MG TABLET PREVACID 30MG SUSPENSION	\$206.62	2
9	DR	\$132.69	1
10	MONOPRIL 10MG TABLET	\$80.34	2
11	MONOPRIL 40MG TABLET	\$40.17	1
<b>Totals</b>		<b>\$15,916.84</b>	<b>106</b>

ATTACHMENT G

**Top 25 Other Drugs (not on the PDL) Granted Standing Prior Authorization**

Rank	Drug Name	Amount Paid	Rx Count
1	OXYCONTIN 80MG TABLET SA	\$181,420.35	245
2	OXYCONTIN 40MG TABLET SA	\$116,104.07	284
3	COPAXONE 20MG INJECTION KIT	\$114,429.88	71
4	SEROQUEL 200MG TABLET	\$102,898.37	377
5	ZYPREXA 20MG TABLET	\$99,810.25	156
6	ZYPREXA 10MG TABLET	\$91,400.26	207
7	PREVACID 30MG CAPSULE DR*	\$87,271.18	513
8	ZYPREXA 15MG TABLET	\$67,800.14	110
9	SEROQUEL 300MG TABLET	\$63,441.83	162
10	RISPERDAL 3MG TABLET	\$59,573.64	165
11	ZYPREXA 5MG TABLET	\$56,400.20	255
12	NUTROPIN AQ PEN CARTRIDGE	\$56,166.60	12
13	SEROQUEL 100MG TABLET	\$47,315.33	427
14	OXYCONTIN 20MG TABLET SA	\$45,535.74	52
15	PROTONIX 40MG TABLET EC*	\$44,787.00	329
16	RISPERDAL 4MG TABLET	\$43,817.99	102
17	ENBREL 25MG KIT	\$41,612.02	56
18	VIOXX 25MG TABLET*	\$40,716.05	467
19	CELEBREX 200MG CAPSULE*	\$39,740.14	338
20	REBIF 44MCG/0.5ML SYRINGE	\$38,387.43	29
21	RISPERDAL 2MG TABLET	\$38,178.70	171
22	GEMZAR 200MG VIAL	\$32,952.00	30
23	SEROQUEL 25MG TABLET	\$27,140.46	286
24	OXANDRIN 10MG TABLET	\$23,778.23	25
25	NEXIUM 40MG CAPSULE*	\$23,699.57	173
<b>Totals</b>		<b>\$1,584,377.43</b>	<b>5,042</b>

## ATTACHMENT H

### PDL Phase I Cost Savings Data

Feb 17 thru June 30, 2004

Comparison of 5 months prior to implementation of Phase I and 5 months after.

Before PDL Phase I

Service Month	Amount Paid (Total)	Count Unique Utilizers	PUPM (per utilizer per month)	Change in PUPM	PUPM monthly savings
9/30/2003	\$1,737,361.75	16,067	\$108.13		
10/31/2003	\$1,823,504.57	16,513	\$110.43		
11/30/2003	\$1,683,089.52	15,675	\$107.37		
12/31/2003	\$1,887,015.92	16,636	\$113.43		
1/31/2004	\$1,874,257.44	16,603	\$112.89		

After PDL Phase I

2/29/2004	\$1,671,629.37	15,790	\$105.87	\$4.58	\$72,318.20
3/31/2004	\$1,832,440.54	16,846	\$108.78	\$1.67	\$28,132.82
4/30/2004	\$1,769,189.85	16,517	\$107.11	\$3.34	\$55,166.78
5/31/2004	\$1,719,746.50	16,353	\$105.16	\$5.29	\$86,507.37
6/30/2004	\$1,823,890.35	16,690	\$109.28	\$1.17	\$19,527.30

**Cost Savings from Phase I PDL changes**

**\$261,652.47**

Please note that this does not include supplemental rebates or federal rebates

### Drug Classes included in PDL Phase I

HYPOTENSIVES, ACE INHIBITORS

HYPOTENSIVES, ANGIOTENSIN RECEPTOR ANTAGONIST

ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATION

CALCIUM CHANNEL BLOCKING AGENTS

GASTRIC ACID SECRETION REDUCERS

BILE SALT SEQUESTRANTS

ALPHA/BETA-ADRENERGIC BLOCKING AGENTS

BETA-ADRENERGIC BLOCKING AGENTS

LIPOTROPICS

NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE II